Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
about
Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.Engineering New Approaches to Cancer VaccinesDirect delivery of a cytotoxic anticancer agent into the metastatic lymph node using nano/microbubbles and ultrasound.Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanomaTargeting the extracellular membrane-proximal domain of membrane-bound IgE by passive immunization blocks IgE synthesis in vivo.Intralymphatic immunotherapyIn situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particlesIntralymphatic immunotherapy and vaccination in mice.Intralymphatic treatment of flagellin-ovalbumin mixture reduced allergic inflammation in murine model of allergic rhinitis.Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.New routes for allergen immunotherapy.Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial.A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic ImmunityIntradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice.Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administrationClinical practice: Allergen-specific immunotherapy in children: facts and FAQs.Novel routes for allergen immunotherapy: safety, efficacy and mode of action.The ReNAissanCe of mRNA-based cancer therapy.The contribution of biotechnology toward progress in diagnosis, management, and treatment of allergic diseases.Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy.Therapies to Preserve β-Cell Function in Type 1 Diabetes.Allergen immunotherapy: routes, safety, efficacy, and mode of action.Medication with antihistamines impairs allergen-specific immunotherapy in mice.Intra-lymph node injection of biodegradable polymer particles.Adjuvant-Enhanced mRNA Vaccines.Update in the mechanisms of allergen-specific immunotheraphy.Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges.Flexible Macromolecule versus Rigid Particle Retention in the Injected Skin and Accumulation in Draining Lymph Nodes Are Differentially Influenced by Hydrodynamic Size.Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
P2860
Q27687250-36EBA553-B0C0-45E8-8474-4BF4C3305BEAQ28085563-B88F29DF-BD1B-4462-8DF2-45C1B04BD6EAQ28546612-BBE5EDE2-77E5-4061-9CE8-20CB60B543F5Q33840446-B7F12E2C-177A-4592-BE09-940994CD84B8Q34222417-1162A50A-25CE-4E6F-8006-D586309A5265Q35155423-F4BB9E88-E875-47EF-B76B-19345EA1E649Q35229225-524E392B-CA3F-4091-B7E7-3FB86CB1162AQ35389863-4689C59C-9B76-48F1-9253-43746A21F6D2Q35890390-482CAC92-AA73-483B-986E-C4EC5E14D644Q36327129-21D024C5-2F52-4715-810E-49760BF91D97Q36864957-10D6E22B-3306-47EA-8D75-13C8AA3E49B6Q36970017-D72E8884-D2AB-40EC-BE51-7AA4CBD40B4EQ37007590-5A4FEAA8-F749-43E6-A68E-924F3DA6D8D6Q37162647-C55571D3-5FFF-4C71-A864-AF48B19FC7ADQ37290106-A05A53D0-A01A-4DEE-8C9E-DF0BE0814605Q37360660-A3043446-1EB2-4B5A-941F-1B30CAB1ED77Q37820336-30B0756F-1597-4780-87A3-5E9E2E1589E0Q37984572-2587D7A7-969D-4694-92B3-722CBBABE93BQ38255012-4B0F46CE-F4DF-4579-9F87-529543332EE4Q38259275-CC4EA22E-BC16-414C-895A-347E4B580A81Q38297557-D38B366F-7E0C-48FF-AD68-C8B02799EDC2Q38317118-9268AD09-B8A9-48CA-994F-D04282DFC18CQ38662048-99BA457E-F88E-486D-9E5E-7032A821E474Q38912244-93299A05-1DEF-4E7C-B0E0-A89AAB54DD4EQ40143896-AD0A1AF8-6539-4C83-A6D4-E86447703439Q40379964-851D6D85-5DAA-4A19-8C97-4CADD2F284D5Q40420219-11D2A389-3DE8-4D41-843A-6444D7919789Q41273420-FB220756-6C4F-48E7-B918-D8379B8C3403Q47940254-F9FD6402-17B7-41A6-B82E-BACB70FBF84AQ55162750-3E39BF8B-861A-4840-AE88-6536E837F8D2Q55658907-22F7ACC3-D8CC-48D0-9E5B-F868753E0EA3
P2860
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
@de
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
@en
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
@nl
type
label
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
@de
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
@en
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
@nl
prefLabel
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
@de
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
@en
Direct intralymphatic injection of peptide vaccines enhances immunogenicity.
@nl
P2093
P2860
P356
P1476
Direct intralymphatic injection of peptide vaccines enhances immunogenicity
@en
P2093
Häffner AC
Johansen P
Wüthrich B
P2860
P304
P356
10.1002/EJI.200425599
P407
P50
P577
2005-02-01T00:00:00Z